November 2022 - Page 2 of 3

FridayNov 11, 2022 9:00 am

Zacks SCR Uses Lexaria Bioscience Corp. (NASDAQ: LEXX) HYPER-H21-4 Study to Support $15 Share Valuation

Lexaria’s HYPER-H21-4 human clinical study was a success, producing favorable results in treating hypertension when comparing the company’s patented DehydraTECH(TM) CBD with a placeboAccording to a Zacks SCR report, the findings support their $15 share valuation of the companyZacks expects Lexaria to penetrate global markets for hypertension, nicotine delivery and antiviral productsThe hypertension drug market is expected to grow to over $34 billion through 2030, with North America anticipated to hold 35% of the market share According to the World Health Organization (“WHO”), approximately 1.13 billion people worldwide suffer from hypertension (high blood pressure), with only one in five being…

ThursdayNov 10, 2022 9:00 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Maintains Strong Cash Position as It Continues Drug Development Program Pursuing Treatment for GBM

CNS Pharmaceuticals is focused on advancing its clinical development for the Berubicin drug candidate in order to bring meaningful treatment to GBM patientsGBM, which has a low survival rate, has limited treatment options when it progresses after first-line therapyThe company is looking to find a solution with Berubicin and is currently evaluating this drug candidate in a potentially pivotal global studyCNS’s ongoing R&D efforts are boosted by its strong cash position; in its Q2 2022 report, the company announced it had cash of about $9.0 million and working capital of $10.5 million CNS Pharmaceuticals (NASDAQ: CNSP), an oncology drug development…

WednesdayNov 09, 2022 10:30 am

Freight Technologies Inc. (NASDAQ: FRGT) Offers Cloud-Based Technology Solutions to Simplify Over-The-Road Trade Avenues Across USMCA Marketplace

The United States is still the world's largest economy and largest importer and exporter of goods and services – with strong ties to Mexico and CanadaMexico has reached number one as a US trade partner, with a value of $520.12 billion during the first eight months of 2022, followed by CanadaFreight Technologies’ cloud-based marketplace, Fr8App, is simplifying Over-The-Road (“OTR”) trade and reducing the carbon footprint in the industry by directly matching OTR shippers with qualified carriers and provides 24/7 live tracking, quick pay, and driver rating featuresThe company is building strategic relationships with key customers across trade industries, expanding its…

WednesdayNov 09, 2022 9:45 am

Flora Growth Corp. (NASDAQ: FLGC) Defines Path to Profitability and Portfolio Expansion with Proposed Franchise Global Health Inc. Acquisition

Flora Growth signed a definitive agreement with FGH to acquire 100% of all issued and outstanding shares by way of a statutory plan of agreementThe deal is expected to close in December following the presentation of the agreement to shareholders; the acquisition will open Flora to the German and EU medical markets, increasing the company’s international revenue and providing essential distribution to German pharmacies and a growing wholesale marketFGH’s acquisition adds to Flora’s expanding list of subsidiaries which currently comprise Vessel Brand Inc. and JustCBD, among others, and it is expected to deliver at least $3 million in annualized cost…

TuesdayNov 08, 2022 10:30 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Aiming to Address Unmet Patient Needs of Hypertensive Patients

Lexaria just completed its HYPER-H21-4 human clinical hypertension study, posting a sustained drop in blood pressure in normally active hypertensive patientsWith the success of this study, the company is working towards an IND application to seek FDA approval for its patented DehydraTECH(TM)-enabled CBD capsule formulation. 47% of adults live with hypertension but only 24% of them have it under controlWith its DehydraTECH-CBD, Lexaria hopes to not only address the severe unmet patient need associated with hypertension but also tap into a market that is set to be valued at $34 billion by 2030 Lexaria Bioscience (NASDAQ: LEXX), a global leader in…

MondayNov 07, 2022 9:00 am

Flora Growth Corp. (NASDAQ: FLGC) Agreement to Acquire Multi-national Cannabis Operator Positions Company for New Strategic Growth in Europe

Flora Growth is a cannabis cultivator and international brand developer with a strong base of operations at its licensed facility in northern ColombiaFlora recently announced its plans to acquire multi-national operator Franchise Global Health (“FGH”), the latest of its strategic acquisitions designed to boost revenues and expand Flora’s international footprintFGH is focused on the German market, where its subsidiary was the first company to sell cannabisGermany is in turn expected to provide the companies a launching pad for success in Europe, where opportunity is defined by the fact that currently Germany provides 75 to 80 percent of Europe’s cannabis salesFlora…

FridayNov 04, 2022 10:30 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Zero Adverse Effects from Successful HYPER-H21-4 Study of DehydraTECH(TM)-CBD for High Blood Pressure

The CDC reported more than 670,000 annual deaths in the United States with high blood pressure as a primary or contributing causeLexaria's patented DehydraTECH(TM) technology has been shown, through HYPER-H21-4 study, to decrease high blood pressure in subjects through DehydraTECH-CBD-enabled dosingThe global antihypertension drug market was valued at over $22.5 billion in revenue in 2018 and is expected to grow at a CAGR of 3.1%, resulting in a market of over $28.7 billion by 2026 In the United States, uncontrolled high blood pressure is common among adults – with only one in four having the condition under control. According to…

ThursdayNov 03, 2022 9:00 am

Cannabis Regulation in the Spotlight During Midterm Elections at the Heels of Presidential Pardon; Flora Growth Corp. (NASDAQ: FLGC) Leveraging Colombian Stance to Manufacture Products at Lower Costs

President Biden issued a pardon for federally incarcerated inmates with minor marijuana possession charges, urging governors to do the same at the state levelThe President also requested a reclassification of cannabis, as it is currently listed above other drugs which are key factors in the overdose epidemicFlora Growth, through its Colombian cultivation, is producing a higher quality product at lower-than-average cost margins due to the country's stance on cannabis regulations With midterm elections right around the corner, voters in five states – Arkansas, Maryland, Missouri, North Dakota, and South Dakota - will determine the legality of recreational marijuana use within…

WednesdayNov 02, 2022 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Maintains Late 2022/Early 2023 for Full IND Application for DehydraTECH-CBD

Lexaria, through its patented DehydraTECH(TM) technology, is improving the bioavailability of pharmaceuticals and therapeutics (in part) by bypassing first-pass-liver processing, thereby achieving an improved speed of onset, and brain absorption of APIsHypertension currently affects nearly 50% of all American adults, with the American Heart Association describing it as a “silent killer”, and is now being studied for its effects during pregnancyThe company has received positive feedback for its pre-Investigational New Drug meeting from the FDA and has reported that it remains on track to file its full IND application by late 2022/early 2023 It looks to capitalize on the growth of…

TuesdayNov 01, 2022 11:15 am

Mullen Automotive Inc. (NASDAQ: MULN) ‘Strikingly Different’ Test Drive Tour Shines Spotlight on Mullen FIVE

Mullen’s U.S. test drive tour added additional dates, locations based on overwhelming responseTour provides hands-on opportunity to see the Mullen FIVESecond leg of tour, which will feature the Mullen FIVE RS, already in the planning stage Mullen Automotive (NASDAQ: MULN) is ending the year with a bang with its Mullen FIVE “Strikingly Different” U.S. Test Drive Tour (https://ibn.fm/eDWyL). The tour, which features the company’s innovative Mullen FIVE, kicked off in October. With additional locations added based on demand, the tour now has eight stops scheduled throughout November and December. “When we announced the [first] location, we received an overwhelmingly positive…

Spotlighting undiscovered companies with enormous upside potential.

Contact us: (310) 299-1717

Month: November 2022